Full Archive

Let’s get VERY real.

Before we get into the Insulet earnings analysis it’s critical to get VERY real about how drugs like Ozempic and Mounjaro are impacting the overall diabetes market. As everyone should know by now, I am a huge fan of these drugs and the many follow-on offerings in development. As I noted in my post yesterday there are good reasons why shares of Lilly and Novo Nordisk are hitting new highs....

Rational Exuberance

Way back in the 1990’s during the dot com buddle then Federal Reserve Board chairman, Alan Greenspan uttered the now famous phrase “Irrational Exuberance” which many took as an indication that the stock market was overvalued. Today Lilly shares are soaring as sales of Mounjaro are skyrocketing taking Lilly shares along for a ride. Shares of their archrival Novo Nordisk are also soaring as the results of the SELECT trial...

Roller Coaster

One of my favorite Luke Bryan songs is Roller Coaster which when you think about it could be the theme song for Tandem. Here is a short history of Tandem as a publicly traded company. November 14, 2013, goes public closing at $192.60. September 28, 2016, the day Medtronic receives FDA approval for the 670G at the time the first hybrid closed loop insulin delivery system Tandem closes at $79.70. November 3, 2017,...

Taking a “pause”

When you’ve covered this wacky world as long as I have few things surprise you anymore. But once every now and then something new and/or different comes along that makes you sit up and take notice. This happened yesterday while reading the transcript from the Tandem earnings call – more on the results coming – the Tandem communications team has come up with a new term for patients who are...

What will it take?

The quest for a noninvasive glucose monitor has been and continues to be the Holy Grail of diabetes technology. Years ago, it was noninvasive BGM today it is noninvasive CGM. The theory behind all of these efforts is the reason the patient does not monitor their glucose as frequently as they should is they had to suffer the pain of finger sticks. We have long contended the reason patients did...

Walking the walk

Quite frankly very little Dexcom does surprises us anymore. Unlike their main competitor Abbott, Dexcom isn’t about the bluster they are all about execution. They know Abbott is a strong competitor, but they are not scared of them and have actually become a better company because of them. Once again, the company exceeded expectations, raised guidance and showed everyone they aren’t folding. We were particularly impressed with international results as Libre...

Back and forth we go.

Oscar Wilde is famous for saying “Imitation is the sincerest form of flattery” which in essence is the perfect description for Abbott’s earnings call today. Back during ADA their archrival and nemesis Dexcom announced new products targeted at less intensively managed patients. A product which would also work well in the expanding market outside of diabetes. So, what does Abbott do? Yep, you guessed it they also announced they too...